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Abstract: Valsartan is a potent antagonist of the type 1 angiotensin receptor (AT1). By blocking 
the actions of angiotensin II on the AT1, it inhibits vasoconstriction and synthesis of aldosterone 
thus lowering systemic blood pressure. Valsartan has been approved by the FDA for the 
treatment of hypertension in children aged 6 years and older. Valsartan can be dosed once a day 
with a sustained 24-hour effect on blood pressure reduction. The starting dose recommended 
in children is 1.3 mg/kg once daily (maximum 40 mg) which needs adjustment according to 
blood pressure response (dose range 1.3–2.7 mg/kg daily; up to 160 mg). A suspension form 
(4 mg/mL) is available for children who cannot swallow tablets. In patients aged 6 to 16 years, 
valsartan treatment (from a low dose of 10–20 mg to a high dose of 80–160 mg) resulted in 
dose-dependent reductions of 7.9–11.5 mmHg in systolic blood pressure and 4.6–7.4 mmHg 
in diastolic blood pressure. In 1- to 5-year-olds, valsartan (from a low dose of 5–10 mg to a 
high dose of 40–80 mg) reduced the systolic blood pressure by 8.4–8.6 mmHg and the diastolic 
blood pressure by 5.5 mmHg. Similar to adults and other antihypertensive medications, the most 
frequent side effect in children subsequent to valsartan use is headache. Current studies have not 
shown adverse effects on linear growth, weight gain, head growth, or development in children 
aged 1 to 5 years subsequent to valsartan use. Based on limited pediatric data, valsartan appears 
to be well tolerated and efficacious in reducing elevated blood pressure.
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Valsartan is an angiotensin receptor blocker (ARB)
The angiotensin II receptor blockers (ARBs) are drugs designed to inhibit the renin-
angiotensin system (RAS). ARBs interact with the receptor for angiotensin II thereby 
selectively blocking its physiological actions. This class of drugs was developed after 
the angiotensin-converting enzyme (ACE) inhibitors, as an alternative to provide more 
specific inhibition of the RAS.1 Valsartan (trade name Diovan) was the second orally 
active ARB to be marketed in Europe and the USA for the treatment of hypertension 
(HTN) (Table 1).2
The RAS regulates blood pressure through its effect on sodium balance, 
extracellular fluid volume, and renal and systemic vascular resistance. The final 
step of the pathway is the activation of the angiotensin II receptors. The actions 
of angiotensin II are mediated by two types of receptors, type 1 (AT1) and type 2 
(AT2). The influence on blood pressure is exerted through activation of AT1. These 
actions include vasoconstriction of systemic arterioles; activation of the sympathetic 
nervous system; stimulation of aldosterone secretion which results in sodium and 
water reabsorption; smooth muscle cell hypertrophy; and stimulation of vascular and Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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myocardial fibrosis. By blocking the action of angiotensin II 
on the AT1   receptor, valsartan decreases peripheral resistance 
and causes less sodium and water reabsorption in the kidneys 
thereby lowering the blood pressure.3 Additionally, blockage 
of the AT1 receptor leads to a compensatory increase in 
angiotensin II levels which increases stimulation of the AT2 
receptor. In contrast to stimulation of AT1, the stimulation of 
AT2 leads to the inhibition of cell growth, tissue repair, and 
possibly vasodilation.1
The increased stimulation of AT2 could possibly promote 
vasodilation,4,5 and thereby contribute to the blood pres-
sure lowering effect of valsartan. There have been reports 
that AT2 stimulation also has an antiproliferative effect on 
cardiac muscle6 by inhibition of cell growth, promotion of 
cell differentiation, and apoptosis.7 This action could have 
a beneficial influence on cardiac remodeling in response to 
elevated blood pressure.
Advantages of ARBs over the more 
commonly used ACE inhibitors
Due to the direct blockage of angiotensin II, the ARBs do 
not have the same limitations as ACE inhibitors. Bradykinin, 
which is also a substrate for ACE, accumulates with the use 
of ACE inhibitors. This accounts for the two most common 
side effects of ACE inhibitors, cough, and angioedema. 
When there is competitive inhibition of ACE, there can be 
a reactive increase in renin and angiotensin I levels which 
may overcome the blockade effect.8 There are also alternative 
pathways through which angiotensin II is formed indepen-
dently of ACE. In patients on chronic ACE inhibitor treat-
ment, an “angiotensin escape phenomenon” is described, 
whereby the reduced stimulation of AT1 and AT2 receptors 
is counteracted by an increase in AT1 receptor stimulation 
of angiotensin II formed by an alternative pathway.4 The use 
of ARBs circumvents this problem by acting directly on the 
angiotensin II receptor and therefore resulting in complete 
angiotensin II inhibition (Figure 1).
Hypertension in children  
and adolescents
HTN is the most commonly diagnosed disease in the United 
States.9 The recent increase in obesity rates in the US and 
higher incidence and risk for HTN in obese individuals 
has increased the focus on the diagnosis and management 
of high blood pressure. HTN in children can be either 
secondary, in which an underlying cause is identified, or 
primary which is a diagnosis of exclusion that is reached 
after a systematic work-up is done looking for secondary 
causes. Pharmacologic treatment of HTN is indicated 
in the presence of secondary HTN, symptomatic HTN, 
when blood pressure remains elevated in spite of lifestyle 
modifications, and when there is evidence of end organ 
damage.10 The goal of antihypertensive treatment should be 
a reduction of blood pressure to below the 95th percentile 
for gender, age, and height for children without comorbidi-
ties. For children with chronic kidney disease, diabetes, and 
target-organ damage the goal blood pressure should be less 
than the 90th percentile.10 Since there is a lack of studies 
comparing long-term clinical endpoint data of multiple 
antihypertensive medications in children, the initial drug 
is chosen based on the prescribing physicians’ own prefer-
ence. The Fourth report on the diagnosis, evaluation and 
treatment of high blood pressure in children and adolescents 
recommends ACE inhibitors, ARBs, beta blockers, calcium 
channel blockers, and diuretics as acceptable drug classes 
for use in children.10
Role of RAS activation in pediatric 
hypertension
The association between obesity and HTN has been known for 
several decades.11–16 Activation of the RAS in these patients may 
represent an important link between obesity and HTN.17 Since 
adipocytes can produce angiotensinogen, increased adiposity in 
obese patients can lead to inappropriately normal or elevated 
plasma renin activity (PRA).18 Despite increased sodium intake, 
Table 1 Angiotensin receptor blockers
Generic name Trade name Half lifea (metabolite) Pediatric FDA approval Dosing Generic form
valsartan Diovan 6 hours Yes 80–160 mg No
Losartan Cozaar 2 (6–9) hours Yes 50 mg Yes
irbesartanb Avapro 11–15 hours No 150–300 mg No
Telmisartan Micardis 24 hours No 40–80 mg No
Candesartan 
cilexetil
Atacand 9 hours Yes 4–32 mg No
eprosartan Teveten 5–9 hours No 400–800 mg No
Olmesartan Benicar 13 hours Yes 10–40 mg No
Notes: aFrom www.medscape.com; birbesartan in a study at a dose of up to 4.5 mg/kg/day once daily did not appear to lower blood pressure effectively in pediatric patients 
aged 6 to 16 years. Avapro has not been studied in pediatric patients less than 6 years old.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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sodium/water retention, and blood pressure, increased levels 
of angiotensinogen, renin, aldosterone, ACE, and increased 
expression of the angiotensinogen gene in visceral adipose tis-
sue are found in obese patients. The levels of angiotensinogen, 
renin, aldosterone, and ACE decrease after 5% in weight loss 
and the reduction in angiotensinogen expression and levels cor-
relates with reduction in the systolic blood pressure.19 Recently, 
a treatment approach for hypertension based on PRA has been 
proposed. Hypertensive patients with low levels of PRA have 
an excess of sodium and volume, and would benefit more from 
diuretic therapy, whereas patients with high PRA levels would 
respond better to RAS inhibitors.20,21
The effects of RAS that are important in the progression 
of chronic kidney disease (CKD) include intraglomerular 
hypertension and increased filtration of proteins, cell growth, 
inflammation, and fibrosis.22 In view of this; ACE/ARB are 
considered the preferred antihypertensive medications in 
children with kidney disease as inhibition of the RAS can 
additionally decrease the rate of progression of CKD.23,24
Valsartan: pharmacokinetics  
and palatability
Adult studies have shown that the bioavailability of valsartan 
is 23% for the capsule and 39% for the solution.25 Valsartan 
has a higher affinity for the AT1 receptor than losartan, but a 
lower affinity than candesartan, telmisartan, and olmesartan.26 
The half life of the drug is around 7 hours which is shorter 
than the half life of telmisartan and olmesartan, however it 
can be given once a day with a sustained 24-hour effect on 
blood pressure reduction.26 Valsartan undergoes little hepatic 
metabolism and is excreted primarily as the unchanged 
drug via biliary elimination. Most of the drug is excreted in 
the feces, with the rest being renally excreted (7%–13% of 
the drug).26
The pharmacokinetics of valsartan in a pediatric population 
has been studied in a group of children aged 1 to 16 years. 
These patients received a dose of 2 mg/kg of valsartan suspen-
sion up to a maximum dose of 80 mg.   Initially age and body 
size were found to have similar influence in the clearance of 
the drug. However, as valsartan is expected to have minimal 
distribution in fatty tissues, adjustment was done for body size 
using fat free mass. This subsequent analysis accounting for 
body size showed that the effect of increasing age was only 
2% per year on valsartan clearance, which was considered 
to be not significant. Therefore, this study shows that body 
weight dosing up to 80 mg provides comparable exposure in 
children as in adults.3
In pediatric populations, the taste of a medication is an 
important factor to consider in the adherence to a treatment 
regimen. The taste and smell acceptability of several ARBs 
1. Bradykinin accumulates
with ACE inhibitor, and
causes recurrent cough and
angioedema
2. Angiotensin escape phenomenon:
Angiotensin II is generated
independently of ACE (chymase
pathway) diminishing the efficacy
of ACE inhibitors
Increases BP:
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Inactive
peptides
ACE
(lung,
kidney)
ARB
Effects of ACE
Effects of ARB
AT2
AT1
Angiotensinogen
(Liver)
Angiotensin I
Angiotensinogen II
Figure 1 effects of ACe and ARB on the renin angiotensin system.
Abbreviations: ACe, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; SvR, systemic vascular resistance.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
152
Baracco and Kapur
has been compared in young children (4 to 11 years of age) 
and found valsartan to have low ratings of palatability com-
pared to candesartan and telmisartan, which were rated by 
the patients to have better taste.27 However this study gave the 
medications in the form of crushed and pulverized tablets. 
Pediatric patients who are not able to swallow a tablet take 
the suspension form of the medication. A suspension form 
is available for preparation from the tablets for valsartan and 
olmesartan. The taste of valsartan suspension has not been 
compared to other ARBs.
Valsartan: dosing, efficacy, and safety
Valsartan was initially approved in Europe in 1996 and in the 
USA in 1997 for the treatment of HTN in adults. This drug 
has shown efficacy in reducing blood pressure in adult popu-
lations. Additionally, it has been shown to have cardioprotec-
tive effects, with reduced morbidity and mortality in adults 
with heart failure and following myocardial infarction.26 
These effects are comparable to those achieved with ACE 
inhibitors, with the additional benefit of a lower incidence 
of side effects such as cough and angioedema.26
In December of 2007 the FDA approved valsartan for the 
treatment of HTN in children aged 6 to 16 years.28 The start-
ing dose recommended in children is 1.3 mg/kg once daily 
(maximum dose 40 mg) which should be adjusted according 
to blood pressure response. The dose range is 1.3–2.7 mg/kg 
once daily (up to 40–160 mg). A suspension form of the 
drug (4 mg/mL) can be prepared for children who cannot 
swallow tablets or for children for whom the dose does not 
correspond to the available tablet strengths. The recipe for 
preparation of the suspension is available in the valsartan 
package insert.28 An oral suspending vehicle (Ora-Plus®) and 
an oral sweetening vehicle (Ora-Sweet SF®), both registered 
trademarks of Paddock Laboratories, Inc are recommended 
for making the oral suspension. As per the recommenda-
tions, 8 tablets of valsartan (80 mg each) are mixed with 
80 mL of Ora-Plus. After shaking this mix and allowing it 
to stand for 1 hour, 80 mL of the Ora-Sweet SF are added. 
The suspension obtained has a concentration of valsartan of 
4 mg/mL. This suspension can be stored for 30 days at room 
temperature or up to 75 days refrigerated. The exposure to 
valsartan with the suspension is 1.6 times greater than with 
the tablet, therefore when the suspension is replaced by a 
tablet the dose may have to be increased.28
Two studies with the same design except for the ages of 
the study cohort were done to assess the efficacy and safety 
of valsartan in pediatric populations. The studies were con-
ducted in two phases. In Phase I the patients were randomly 
assigned to receive low, medium, and high doses of   valsartan 
for two weeks. Children who completed Phase I were then 
re-randomized to continue the same dose of valsartan or 
to receive placebo for two additional weeks. The study by 
Wells et al29 which included children aged 6 to 16 years 
(n = 261) showed a reduction in systolic and diastolic BP in 
all three study groups (Table 2). Flynn et al’s study30 with a 
similar design including patients aged 1 to 5 years (n = 90) 
also showed reduction in both systolic and diastolic blood 
pressure (Table 2). However, it is important to note that the 
reduction in the systolic and diastolic BP is dose dependent 
in older children (6 to 16 years)29 while this effect was not 
reported in the younger age group (1 to 5 years).30 It should 
be noted that both studies do not comment on the statistical 
significance of reduction in the systolic and diastolic BP 
noted in study Phase I.
In Phase II, in 6- to 16-year-olds, the systolic blood 
pressure of patients who continued to receive valsartan at 
medium (40–80 mg) and high doses (80–160 mg) was 4 and 
7 mmHg lower than patients who received placebo.29 The 
statistical significance of this reduction was not mentioned. 
In 1- to 5-year-olds the mean difference in the change of 
systolic (3.9 mmHg, P = 0.02) and diastolic blood pressures 
(3.7 mmHg, P , 0.01) between the pooled valsartan and 
placebo groups was significant.30
Prescription patterns for ARB
The therapeutic efficacy of ARB when compared to ACE 
inhibitors is a critical issue and one that has important 
implications for ARB prescriptions. Currently there is no 
consensus as to whether pharmacological differences between 
ACE inhibitors and ARB translate into significant differ-
ences in therapeutic outcomes. Existing literature suggests 
that the antihypertensive effects of ARB are similar to ACE 
Table 2 Results of randomized, double-blind clinical studies on 
the safety and effectiveness of valsartan in children
Valsartan dose 
group
Dose according to 
patients’ weight (mg)
Blood pressure 
reduction (mmHg)
Wells et al29
,35 kg $35 kg SBP DBP
Low dose 10 20 7.9 4.6
Medium dose 40 80 9.6 5.8
High dose 80 160 11.5 7.4
Flynn et al
,18 kg $18 kg SBP DBP
Low dose 5 10 8.4 5.5
Medium dose 20 40 8.3 6.4
High dose 40 80 8.6 5.5
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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inhibitors and that they are an acceptable alternative as first 
choice drugs for the management of hypertension especially 
in patients intolerant to ACE inhibitors.31 In adults, ACE 
inhibitors are the drug of choice in heart failure, cardiac 
dysfunction after MI, and diabetic nephropathy, and ARBs 
offer an acceptable alternative. A retrospective study evaluat-
ing the use of ARBs as antihypertensives showed that 53.4% 
of the patients were new to all antihypertensive therapies and 
more than 40% of these had no other antihypertensive. The 
study also reported increased use of fixed drug combina-
tions with diuretics when losartan and valsartan were used 
initially to control BP in comparison to the newer ARB such 
as telmisartan, irbesartan, or candesartan.32
In children, the FDA has approved the use of valsartan 
for elevated blood pressure for those who are older than 6 
years of age. In addition to the reduction of blood pressure, 
valsartan’s antiproteinuric effects contribute towards addi-
tional benefit in children with CKD.33,34 Although ARBs 
have shown to be effective in the reduction of proteinuria 
and the rate of progression of renal failure,35,36 there is limited 
information regarding the renoprotective effects of ARBs in 
children with CKD. A study in children (n = 10) with CKD 
showed that adding an ARB (losartan) to ACE inhibitor treat-
ment further reduced proteinuria.37 Valsartan may have an 
important role in this population and more studies are needed 
in children with CKD to further determine the benefits of 
valsartan in slowing the progression of renal disease. There 
is a clinical trial being conducted to compare the long-term 
safety and effectiveness of valsartan in combination with 
enalapril versus enalapril alone in children with CKD. This 
trial will also evaluate proteinuria reduction, renopreserva-
tion and tolerability of valsartan and enalapril in combination 
versus enalapril monotherapy in patients with CKD.38
Valsartan versus other ARBs
A meta-analysis of published randomized controlled trials 
involving ARB (valsartan, losartan, irbesartan, and cande-
sartan) has shown a similar blood pressure lowering efficacy 
within the ARB class, a flat ARB-dose response when 
titrating from lower to maximum recommended doses, and 
potentiation of the antihypertensive effect with the addition 
of a diuretic (hydrochlorthiazide).39 In children, studies are 
needed to compare the efficacy of the different ARBs. It is 
possible that olmesartan may offer a better alternative in view 
of its longer half life (Table 1) and therefore better control 
with daily dosing.
Valsartan in combination with other antihypertensives is 
widely used in adults. These combinations have been shown 
to have better efficacy than valsartan monotherapy in the 
reduction of blood pressure.40 The commercially available 
combinations include: 1) Valturna (valsartan with aliskiren, 
a direct renin inhibitor); 2) Exforge (valsartan and amlo-
dipine, calcium channel blocker); 3) Diovan HCT (valsartan 
and hydrochlorothiazide, diuretic); and 4) Exforge HCT 
(valsartan with both amlodipine and hydrochlorothiazide). 
These combinations have not yet been approved for use in 
children.
Valsartan: side effects
Adverse reactions to valsartan are generally mild and 
  transient. The discontinuation rate due to adverse effects is 
only 2.3%. The most common reasons for discontinuation 
of this drug are headache and dizziness.28 Cardiovascular 
side effects of ARBs are similar to other antihypertensives 
and include hypotension, postural hypotension, and syncope. 
Central nervous system side effects include dizziness, fatigue, 
postural dizziness, headache, blurred vision, and vertigo. 
Gastrointestinal side effects include diarrhea, abdominal 
pain, and nausea; rarely do ARBs cause elevated liver 
enzymes. Hematologic side effects include neutropenia and 
decrease in hemoglobin. The incidence of cough is 2.6%, 
which is less than when taking ACE inhibitors.28 Renal side 
effects include hyperkalemia and renal dysfunction with 
elevated creatinine. Musculoskeletal side effects include 
arthralgia and back pain. Rash can also be caused by ARBs 
and angioedema has also been reported although it is con-
sidered to be a rare side effect.
Drugs that inhibit the renin-angiotensin system can cause 
fetal defects if used during pregnancy. These defects include 
neonatal skull hypoplasia, anuria, oligohydramnios associ-
ated with craniofacial deformities and hypoplastic lungs, 
prematurity, renal failure, intrauterine growth retardation, 
patent ductus arteriosus, and death. In pediatrics, if used in 
female adolescents they should be counseled regarding these 
risks and if sexually active should take contraceptives or be 
prescribed alternative antihypertensives.
Although the risk of derangement of liver function tests, 
potassium, and creatinine is low, the prescriber may want 
to consider monitoring these tests when valsartan therapy 
is started.
A recent warning has been issued by the FDA regarding 
the possible association between the use of ARB and cancer. 
This warning is based on a recent meta-analysis that reported 
the frequencies of new cancer occurrence to be 7.2% for 
patients receiving ARBs compared to 6.0% for patients not 
taking ARBs. The risk ratio was 1.08 with a 95% confidence Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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interval of 1.01–1.15.41 However, this study has several limi-
tations and the FDA has not concluded that ARBs increase 
the risk of cancer and is still evaluating this safety concern. In 
children, the duration of ARB therapy could be longer given 
their young age; therefore the association between ARB and 
cancer could possibly influence the prescription patterns for 
this medicine class.
Overall, in the clinical studies that looked at the safety of 
valsartan in children,29,30 this drug was well tolerated. In the 
6- to 16-year-old group there was a similar adverse event pro-
file to that seen in adults, with headache as the most frequent 
adverse event noted.29 The 1- to 5-year-old group had a low 
incidence of adverse events, with the most frequent being 
cough, fever, upper respiratory infection, and diarrhea which 
are common illnesses in children in that age group. Four 
patients had increases in liver enzymes; however, no relation-
ship to the study drug could be determined. The effects of 
treatment with valsartan on growth and development were 
studied in this age group. Valsartan did not appear to have 
adverse effects on linear growth, weight gain, head growth, 
or development over the 13 months of the study.30
Summary
Valsartan is one of the ARBs that are FDA approved for 
use in hypertensive children. This drug has a high affin-
ity for the AT1 receptor and lowers the blood pressure by 
inhibiting vasoconstriction and synthesis of aldosterone. In 
comparison to ACE inhibitors, valsartan blocks the actions 
of angiotensin II by inhibiting its interaction with AT1. Thus, 
valsartan and other ARBs have fewer side effects of recurrent 
cough and angioedema in comparison to ACE inhibitors. 
Valsartan is a good candidate for the treatment of hyperten-
sive children as it has been shown to be effective in reducing 
systolic and diastolic blood pressure and is well tolerated.29,30 
The activation of the RAS is a contributing factor in progres-
sive CKD; therefore valsartan is a good choice for managing 
hypertension and/or proteinuria in children with CKD.
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